Heart disease

Cardiac safety and disease models

Cardiovascular disease is the primary source of death in the world, killing more than 20 million people every year through conditions, such as heart attack, stroke and heart failure. We at Fluicell are dedicated to advancing cardiac health by providing transformative tissue engineering solutions for research, drug development and regenerative medicine.

With our Biopixlar high-resolution 3D bioprinting technology, we are able to engineer functional cardiac tissues for use as in vitro research models or for regenerative research applications with cell level precision. Using Biopixlar, you can create everything from complex cardiac tissue sections that accurately mimic human histology to precisely engineered cardiac organoids.

Microscope image of bioprinted cardiac tissue

Bioprinted cardiac models

Fluicell’s tissue engineering technology allows us to target heart disease and cardiac safety in multiple ways. We are currently developing cardiac tissue models with applications across cardiac safety screening as well as cardiac disease modeling. Most currently used cell-based cardiac models are either monocultures or simple mixtures, and do not account for cell type diversity, ECM composition, cell-cell interactions, and microenvironment geometry. Our advanced cardiac models are developed to target some of the main challenges to achieve fully predictive in vitro models:

  • Ability to replicate complex microenvironment and interplay between the cell types beyond simple cardiomyocyte monoculture
  • Ability to Replicate role for each cell type in maintaining homoestasis and restoration of function upon acute damage or toxic exposure
  • Accurate representation of the organ tissue composition
  • Having repeatable on-demand tissues to fit into regulatory systems

Screening models for safety pharmacology screening

Fluicell is engaged in the development of human tissue-based models for cardiac safety screening. Cardiac toxicity is a common cause of drug candidates failing in the clinical phase, and new advanced models that can provide predictive answers earlier in the development process can lead to major cost savings. Since 2021, Fluicell has conducted product development in the field in collaboration with a top-10 pharmaceutical company and is currently actively collaborating with the goal of investigating the possibility of integrating Fluicell's bioprinted tissues into the pharmaceutical company's workflows.

The collaboration is expected to be completed in early 2024.

what our customers say

Fluicell’s technology is the first of its kind to enable single-cell resolution bioprinting with precision, speed and reproducible accuracy, even in 3D, in a way that was not possible before.

Dr. Luiz Bertassoni, Director Knight Cancer Precision Biofabrication Hub

The BioPen System is one of the best single-cell treatment systems on the market. It is easy-to-use, and gives me beautiful, publication-ready movies.

Dr. Dani Cai, National Institute of Health

The BioPen system provides us with unique data; with it, you are able to see how cell processes are trapped.

Prof. Megan Rizzo, University of Maryland Medical Center

The BioPen product is well designed and works even better than we could have hoped. The team is very reliable with customer support. I would highly recommend purchasing this product.

Dr. Veronica Jove, Rockefeller University

The Dynaflow Resolve system is a very reliable and efficient tool for automated compound application with excellent performance in fast solution exchange.

Dr. Timm Danker, NMI TT

Previous

Next

Partner with us!

Learn about what we hope to achieve in partnership with innovation-driven pharmaceutical companies. Have questions or interested in exploring a collaboration? Get in touch.